Esperion Therapeutics, Inc. (ESPR) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Esperion Therapeutics, Inc. (ESPR) Bundle
Evaluate Esperion Therapeutics, Inc.'s financial outlook with expertise! This (ESPR) DCF Calculator provides pre-filled financial data along with full flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your predictions.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 148.4 | 227.5 | 78.4 | 75.5 | 116.3 | 127.4 | 139.6 | 152.9 | 167.5 | 183.5 |
| Revenue Growth, % | 0 | 53.37 | -65.52 | -3.79 | 54.14 | 9.55 | 9.55 | 9.55 | 9.55 | 9.55 |
| EBITDA | -88.7 | -120.3 | -222.1 | -176.3 | -150.1 | -105.2 | -115.2 | -126.2 | -138.3 | -151.5 |
| EBITDA, % | -59.8 | -52.88 | -283.18 | -233.65 | -129.03 | -82.54 | -82.54 | -82.54 | -82.54 | -82.54 |
| Depreciation | .3 | .5 | .6 | .5 | .2 | .5 | .6 | .6 | .7 | .7 |
| Depreciation, % | 0.21501 | 0.24039 | 0.78014 | 0.66247 | 0.14097 | 0.4078 | 0.4078 | 0.4078 | 0.4078 | 0.4078 |
| EBIT | -89.0 | -120.9 | -222.8 | -176.8 | -150.3 | -105.3 | -115.4 | -126.4 | -138.4 | -151.7 |
| EBIT, % | -60.02 | -53.12 | -283.96 | -234.31 | -129.17 | -82.63 | -82.63 | -82.63 | -82.63 | -82.63 |
| Total Cash | 166.1 | 305.0 | 208.9 | 124.8 | 82.2 | 120.0 | 131.4 | 144.0 | 157.7 | 172.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 12.4 | 22.9 | 33.7 | 48.5 | 30.9 | 33.8 | 37.0 | 40.6 | 44.4 |
| Account Receivables, % | 0 | 5.44 | 29.24 | 44.69 | 41.69 | 24.21 | 24.21 | 24.21 | 24.21 | 24.21 |
| Inventories | .0 | 16.1 | 34.4 | 35.2 | 65.6 | 39.2 | 43.0 | 47.1 | 51.6 | 56.5 |
| Inventories, % | 0 | 7.09 | 43.84 | 46.64 | 56.41 | 30.8 | 30.8 | 30.8 | 30.8 | 30.8 |
| Accounts Payable | 28.9 | 52.0 | 17.6 | 23.0 | 31.7 | 31.2 | 34.2 | 37.5 | 41.0 | 45.0 |
| Accounts Payable, % | 19.45 | 22.84 | 22.38 | 30.53 | 27.26 | 24.49 | 24.49 | 24.49 | 24.49 | 24.49 |
| Capital Expenditure | -1.0 | -13.4 | .0 | .0 | .0 | -1.7 | -1.8 | -2.0 | -2.2 | -2.4 |
| Capital Expenditure, % | -0.64234 | -5.88 | 0 | 0 | 0 | -1.3 | -1.3 | -1.3 | -1.3 | -1.3 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -99.9 | -139.9 | -263.9 | -217.8 | -150.3 | -105.3 | -115.4 | -126.4 | -138.4 | -151.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -71.7 | -158.2 | -326.5 | -223.5 | -186.6 | -62.9 | -120.3 | -131.8 | -144.4 | -158.2 |
| WACC, % | 10.31 | 10.31 | 10.31 | 10.31 | 10.31 | 10.31 | 10.31 | 10.31 | 10.31 | 10.31 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -448.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -161 | |||||||||
| Terminal Value | -1,941 | |||||||||
| Present Terminal Value | -1,188 | |||||||||
| Enterprise Value | -1,637 | |||||||||
| Net Debt | 459 | |||||||||
| Equity Value | -2,096 | |||||||||
| Diluted Shares Outstanding, MM | 103 | |||||||||
| Equity Value Per Share | -20.32 |
What You Will Get
- Real Esperion Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Esperion Therapeutics, Inc. (ESPR).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to Esperion.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Esperion’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Esperion Therapeutics, Inc. (ESPR).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility in your analysis of Esperion.
Key Features
- 🔍 Real-Life ESPR Financials: Pre-filled historical and projected data for Esperion Therapeutics, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Esperion’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Esperion’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download the Template: Gain immediate access to the Excel-based ESPR DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Esperion’s intrinsic value.
- Test Scenarios: Experiment with different assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the results to inform your investment or financial strategy.
Why Choose Esperion Therapeutics, Inc. (ESPR)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Proven Efficacy: Clinical trials demonstrate the effectiveness of our treatments in improving patient outcomes.
- Patient-Centric Approach: Focused on developing therapies that enhance the quality of life for patients.
- Strong Scientific Foundation: Backed by robust research and development efforts from leading experts in the field.
- Commitment to Accessibility: Striving to make our therapies available to those who need them most.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Esperion Therapeutics, Inc. (ESPR) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Esperion Therapeutics, Inc. (ESPR).
- Consultants: Deliver professional valuation insights on Esperion Therapeutics, Inc. (ESPR) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like Esperion Therapeutics, Inc. (ESPR) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios involving Esperion Therapeutics, Inc. (ESPR).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Esperion Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Esperion Therapeutics, Inc. (ESPR).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.